JP2023518414A - 治療のための細胞外小胞 - Google Patents

治療のための細胞外小胞 Download PDF

Info

Publication number
JP2023518414A
JP2023518414A JP2022556038A JP2022556038A JP2023518414A JP 2023518414 A JP2023518414 A JP 2023518414A JP 2022556038 A JP2022556038 A JP 2022556038A JP 2022556038 A JP2022556038 A JP 2022556038A JP 2023518414 A JP2023518414 A JP 2023518414A
Authority
JP
Japan
Prior art keywords
antigen
scaffold
linked
aspects
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022556038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518414A5 (https=
Inventor
スリラム サティヤナラヤナン，
ティム スース，
ケ シュー，
アーロン ノイス，
ケビン ピー． ドゥーリー，
エリック ジャン，
クリスティーン マッコイ，
ジョナサン フィン，
Original Assignee
コディアック バイオサイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/024023 external-priority patent/WO2020191361A2/en
Application filed by コディアック バイオサイエンシーズ， インコーポレイテッド filed Critical コディアック バイオサイエンシーズ， インコーポレイテッド
Publication of JP2023518414A publication Critical patent/JP2023518414A/ja
Publication of JP2023518414A5 publication Critical patent/JP2023518414A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2022556038A 2020-03-20 2021-03-22 治療のための細胞外小胞 Pending JP2023518414A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
PCT/US2020/024023 WO2020191361A2 (en) 2019-03-21 2020-03-20 Extracellular vesicles for vaccine delivery
USPCT/US2020/024023 2020-03-20
US202063001088P 2020-03-27 2020-03-27
US63/001,088 2020-03-27
US202063003171P 2020-03-31 2020-03-31
US63/003,171 2020-03-31
US202063006585P 2020-04-07 2020-04-07
US63/006,585 2020-04-07
US202063017514P 2020-04-29 2020-04-29
US63/017,514 2020-04-29
US202163142418P 2021-01-27 2021-01-27
US63/142,418 2021-01-27
PCT/US2021/023485 WO2021189047A2 (en) 2020-03-20 2021-03-22 Extracellular vesicles for therapy

Publications (2)

Publication Number Publication Date
JP2023518414A true JP2023518414A (ja) 2023-05-01
JP2023518414A5 JP2023518414A5 (https=) 2024-04-16

Family

ID=77771656

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022556038A Pending JP2023518414A (ja) 2020-03-20 2021-03-22 治療のための細胞外小胞

Country Status (6)

Country Link
US (1) US20250114445A1 (https=)
EP (1) EP4121450A2 (https=)
JP (1) JP2023518414A (https=)
AU (1) AU2021236763A1 (https=)
CA (1) CA3171623A1 (https=)
WO (1) WO2021189047A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3965829A4 (en) 2019-05-06 2023-05-24 Malcolm, Thomas ADAPTED HYPOIMMUNE NANOVESICULAR DELIVERY SYSTEM FOR CANCER TUMORS
WO2022013609A1 (en) * 2020-07-13 2022-01-20 Immunovaccine Technologies, Inc. Sars-cov-2 vaccine compositions and methods of preparation and use
WO2023056468A1 (en) * 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist
US20250000967A1 (en) * 2021-11-10 2025-01-02 Ck-Exogene Co., Ltd. Exosome-based antiviral vaccine and manufacturing method thereof
WO2023230233A1 (en) * 2022-05-25 2023-11-30 Malcolm Thomas Allogeneic hypoimmune biomimetic nanovesicle for the treatment of cancer
KR20240010702A (ko) * 2022-07-13 2024-01-24 (주)엑솔런스 항원 단백질 또는 상기 단백질을 암호화하는 유전자를포함하는 세포외소포체 및 그의 용도
US20260055404A1 (en) * 2022-08-17 2026-02-26 Lonza Sales Ag Extracellular vesicle comprising a biologically active molecule and a cell penetrating peptide cleavable linker
WO2024237866A1 (en) * 2023-05-17 2024-11-21 National University Of Singapore Surface display of immunotherapeutics on extracellular vesicles and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006518212A (ja) * 2003-02-14 2006-08-10 アノシス・インコーポレーテッド 抗体を生成し抗体レパートリーをスクリーニングするための方法とコンパウンド
WO2019133934A2 (en) * 2017-12-28 2019-07-04 Codiak Biosciences, Inc. Exosomes for immuno-oncology and anti-inflammatory therapy
WO2019183578A1 (en) * 2018-03-23 2019-09-26 Codiak Biosciences, Inc. Extracellular vesicles comprising sting-agonist

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
AU2004254600A1 (en) 2003-06-26 2005-01-13 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
CA2627105A1 (en) 2005-10-26 2007-05-03 Protelix, Inc. Influenza combinatorial antigen vaccine
CN101790380B (zh) 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
US8426565B2 (en) 2007-08-30 2013-04-23 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
US9421254B2 (en) 2007-09-24 2016-08-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunostimulatory combinations of TLR ligands and methods of use
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2010014913A1 (en) 2008-08-01 2010-02-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
CA2777198C (en) 2009-10-06 2018-07-24 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer
EP3195868A3 (en) 2010-10-01 2017-08-02 VentiRx Pharmaceuticals, Inc. Therapeutic use of a tlr agonist and combination therapy
PL3892295T3 (pl) 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
WO2013053008A2 (en) 2011-10-14 2013-04-18 The Walter And Eliza Hall Institute Of Medical Research Molecules which bind clec9a
EP2858722B8 (en) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
US9840533B2 (en) 2013-04-29 2017-12-12 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
WO2014189806A1 (en) 2013-05-18 2014-11-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
CR20160564A (es) 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos como moduladores de sting
EP3546473B1 (en) 2014-12-16 2025-12-10 Kayla Therapeutics Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
WO2016096577A1 (en) 2014-12-16 2016-06-23 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
AU2016262823A1 (en) * 2015-05-18 2017-12-07 Universita' Degli Studi Di Trento Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
KR102222186B1 (ko) 2015-08-13 2021-03-03 머크 샤프 앤드 돔 코포레이션 Sting 효능제로서 시클릭 디-뉴클레오티드 화합물
JP2018534295A (ja) 2015-10-28 2018-11-22 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
PT3440076T (pt) 2016-04-07 2022-07-29 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas úteis como modeladores de proteína
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
PE20210255A1 (es) 2016-12-01 2021-02-10 Takeda Pharmaceuticals Co Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon)
IL272786B2 (en) 2017-08-25 2025-03-01 Codiak Biosciences Inc Preparation of therapeutic exosomes using membrane proteins
WO2019099942A1 (en) 2017-11-17 2019-05-23 Codiak Biosciences, Inc. Compositions of engineered exosomes and methods of loading luminal exosomes payloads
SMT202200156T1 (it) 2018-11-16 2022-05-12 Codiak Biosciences Inc Vescicole extracellulari ingegnerizzate e loro usi
BR112021018694A2 (pt) 2019-03-21 2021-11-30 Codiak Biosciences Inc Vesículas extracelulares para distribuição de vacina

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006518212A (ja) * 2003-02-14 2006-08-10 アノシス・インコーポレーテッド 抗体を生成し抗体レパートリーをスクリーニングするための方法とコンパウンド
WO2019133934A2 (en) * 2017-12-28 2019-07-04 Codiak Biosciences, Inc. Exosomes for immuno-oncology and anti-inflammatory therapy
WO2019183578A1 (en) * 2018-03-23 2019-09-26 Codiak Biosciences, Inc. Extracellular vesicles comprising sting-agonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VIROLOGY, vol. 362, JPN6025007968, 2007, pages 26 - 37, ISSN: 0005664292 *

Also Published As

Publication number Publication date
WO2021189047A2 (en) 2021-09-23
AU2021236763A1 (en) 2022-10-06
US20250114445A1 (en) 2025-04-10
WO2021189047A3 (en) 2021-11-04
EP4121450A2 (en) 2023-01-25
CA3171623A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
US11992527B2 (en) Extracellular vesicles for vaccine delivery
JP2023518414A (ja) 治療のための細胞外小胞
TWI846697B (zh) 工程化細胞外囊泡及其用途
US20250154218A1 (en) IL-2 Conjugates and Methods of Use to Treat Autoimmune Diseases
US20240082389A1 (en) Methods of producing extracellular vesicles
JP2022525924A (ja) 細胞外小胞コンジュゲート及びその使用
US20230181758A1 (en) Extracellular vesicles targeting dendritic cells and uses thereof
US20230114434A1 (en) Extracellular vesicles for treating neurological disorders
US20220251200A1 (en) Extracellular vesicles targeting t cells and uses thereof
JP2022519275A (ja) エクソソーム操作のための膜タンパク質足場
US12433954B2 (en) Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240321

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250227

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250818